Topic summary

Why a compound being unapproved is not the same as being illegal to possess

Sourcing › Regulatory FDA MHRA research use only EMA personal import

This is a generated summary. It shows the 9 most-liked posts from a topic of 79, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.nybergTL2 Moderator19 Jul 2025#5

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

30 likes 12mo

b.demirTL2 Moderator29 Aug 2025 · edited#13

Picking up post #10: that is the part I would want checked first.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

30 likes 11mo

d.bramleyTL3Regular18 Oct 2025#25

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

27 likes 9mo

to.vargaTL2 Moderator16 Dec 2025#41

owen.brady, post #18: Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had been repeating something I had not checked carefully enough. Go to post

Coming back to post #39, because the follow-up matters more than the original answer.

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

27 likes in reply to #18 7mo

l.parkinsonTL2Member29 Jan 2026#54

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

32 likes 6mo

z.szaboTL2 Moderator8 Feb 2026#57

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

23 likes 6mo

k.brandl_deTL3Translator · DE12 Mar 2026 · edited#67

I read post #65 twice before replying, because I had assumed the opposite.

31 likes 5mo

y.rahimiTL2 Moderator21 Mar 2026#70

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

24 likes 4mo

dietitian_hollisTL3Dietitian5 Apr 2026#75

a.cabrera, post #30: Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary. Go to post

This follows post #72 rather than contradicting it.

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

25 likes in reply to #30 4mo

Read the full topic (79 posts)

This topic was referenced in

Research-use-only labelling: what it means and what it does notSourcing › Regulatory · 110 replies
Follow-up: How compounding permissions changed when supply normalisedSourcing › Regulatory · 77 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d
What a regulator's shortage notice actually authorises Sourcing › Regulatory personal import research use only EMA FDA Solved What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…	+8	12	15k	17h
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion, following the…	+72	77	1.5k	1d
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA EMA compounding research use only Closed On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…	+76	82	52k	11mo
About the Regulatory category Sourcing › Regulatory research use only compounding FDA Pinned Wiki Research-use-only status, compounding rules, import restrictions, and the primary documents behind them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…		4	49k	4mo

Related topics — sharing the tags FDA, MHRA, research use only

Topic	Participants	Replies	Views	Activity
Personal import allowances, compared — a second dataset Access › International personal import telehealth MHRA EMA Wiki Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…	+124	132	9.2k	2mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d
Payment method and the leverage it gives you, ranked Sourcing › Payments research use only payments documentation quality Solved Closed Posting this under the heading it deserves: Payment method and the leverage it gives you, ranked Everything below is what sits behind that. Structured report rather than an opinion, following the format the…	+71	76	56k	10mo
A payment that went through twice: how it was resolved Sourcing › Payments payments research use only documentation quality Solved Closed A payment that went through twice: how it was resolved Writing it up because I had to work it out twice and would rather nobody else did. I would like to talk about documentation quality as a signal,…	+20	24	55k	3mo
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…	+37	42	32k	11d